Norgine on a growth charge again with Theravia takeover deal

Norgine on a growth charge again with Theravia takeover deal

Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition of France's Theravia for an undisclosed sum.

Norgine agrees to acquire pharma laboratory Theravia

This transaction is said to be contingent on receiving customary regulatory approvals. Theravia’s portfolio includes Siklos for sickle cell disease and Orphacol for genetic disorders affecting the liver’s The post Norgine agrees to acquire Theravia appeared first on Pharmaceutical Business review.

Latest News Norgine strengthens rare disease portfolio with acquisition of Theravia - Businessfortnight

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine’s strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine’s position as a partner of choice for commercialising rare and specialty pharmaceuticals in Europe PARIS, April 15, 2025 /PRNewswire/ — Norgine and Theravia announced today that they have entered into a definitive ag…